PURPOSE OF REVIEW: Synovial sarcomas are regarded as chemosensitive tumors compared to other types of soft tissue sarcomas, however, prognosis for advanced refractory disease remains poor. In light of the vascular nature of sarcomas, current molecularly targeted therapies aim at an antiangiogenic approach to management of this disease. RECENT FINDINGS: Recent studies with oral vascular endothelial growth factor receptor (VEGFR) inhibitors such as sunitinib, sorafenib and cediranib have shown disease stabilization in patients with advanced synovial sarcoma. Forty-nine percent of patients with synovial sarcoma on the phase II trial of pazopanib had no evidence of disease progression at 12 weeks. SUMMARY: The overall impact of chemotherapy on survival has been minimal in advanced soft tissue sarcomas. Anti-VEGF therapies have resulted in improved outcomes for patients with various solid tumors, and have shown preliminary evidence of activity in synovial sarcomas. Combinations of anti-VEGF therapies with agents targeting other pathways dysregulated in sarcomas have the potential to improve the outcome of this difficult-to-treat disease.
PURPOSE OF REVIEW: Synovial sarcomas are regarded as chemosensitive tumors compared to other types of soft tissue sarcomas, however, prognosis for advanced refractory disease remains poor. In light of the vascular nature of sarcomas, current molecularly targeted therapies aim at an antiangiogenic approach to management of this disease. RECENT FINDINGS: Recent studies with oral vascular endothelial growth factor receptor (VEGFR) inhibitors such as sunitinib, sorafenib and cediranib have shown disease stabilization in patients with advanced synovial sarcoma. Forty-nine percent of patients with synovial sarcoma on the phase II trial of pazopanib had no evidence of disease progression at 12 weeks. SUMMARY: The overall impact of chemotherapy on survival has been minimal in advanced soft tissue sarcomas. Anti-VEGF therapies have resulted in improved outcomes for patients with various solid tumors, and have shown preliminary evidence of activity in synovial sarcomas. Combinations of anti-VEGF therapies with agents targeting other pathways dysregulated in sarcomas have the potential to improve the outcome of this difficult-to-treat disease.
Authors: X Xin; S Yang; G Ingle; C Zlot; L Rangell; J Kowalski; R Schwall; N Ferrara; M E Gerritsen Journal: Am J Pathol Date: 2001-03 Impact factor: 4.307
Authors: Sam S Yoon; Neil H Segal; Peter J Park; Kara Y Detwiller; Namali T Fernando; Sandra W Ryeom; Murray F Brennan; Samuel Singer Journal: J Surg Res Date: 2006-10 Impact factor: 2.192
Authors: M G Achen; M Jeltsch; E Kukk; T Mäkinen; A Vitali; A F Wilks; K Alitalo; S A Stacker Journal: Proc Natl Acad Sci U S A Date: 1998-01-20 Impact factor: 11.205
Authors: Brian I Rini; Jorge A Garcia; Matthew M Cooney; Paul Elson; Allison Tyler; Kristi Beatty; Joseph Bokar; Tarek Mekhail; R M Bukowski; G Thomas Budd; Pierre Triozzi; Ernest Borden; Percy Ivy; Helen X Chen; Afshin Dolwati; Robert Dreicer Journal: Clin Cancer Res Date: 2009-09-22 Impact factor: 12.531
Authors: Yan Qi; Shuang-Shuang Dong; Yong-Lai He; Zi-Han Liu; Ya-Lan Huang; Ning Wang; Zhen Zhang; Zhong Li; Mei Er Tu He Ta Mi Shi; Xiao Feng; Qing Yao; Hong Zou; Jian-Ming Hu; Li-Juan Pang; Feng Li Journal: BMC Cancer Date: 2022-02-12 Impact factor: 4.430